Nicollet Investment Management Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,770 shares of the company’s stock after selling 1,399 shares during the period. Johnson & Johnson makes up approximately 1.6% of Nicollet Investment Management Inc.’s investment portfolio, making the stock its 16th largest holding. Nicollet Investment Management Inc.’s holdings in Johnson & Johnson were worth $3,504,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in JNJ. Family CFO Inc acquired a new position in Johnson & Johnson in the fourth quarter valued at about $26,000. Steward Financial Group LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at about $34,000. Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $38,000. Advocacy Wealth Management Services LLC grew its stake in Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after acquiring an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $49,000. 68.78% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
JNJ has been the topic of a number of research reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. UBS Group cut their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Wells Fargo & Company boosted their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. The Goldman Sachs Group boosted their price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Finally, Raymond James upped their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $189.89.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $171.11 on Friday. The business’s 50 day moving average price is $175.21 and its two-hundred day moving average price is $174.55. The company has a market cap of $449.88 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 3.32 and a beta of 0.59. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.48 earnings per share. On average, analysts predict that Johnson & Johnson will post 10.05 EPS for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.64%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.